Back

Cardioprotective potential of exosomes derived from blood outgrowth endothelial cells in ischemic cardiomyopathy

25 August 2023 (11:15 - 11:50)
Organised by: Logo
Congress Presentation Part of: Drug-related risk management in chronic coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

About the speaker

Photo
Doctor Ming Wu

KU Leuven, Leuven (Belgium)

6 More presentations in this session

Presentation thumbnail
Risk of myocardial infarction following capecitabine treatment in patients with gastrointestinal cancer - a nationwide registry-based study
Doctor J. Shanmuganathan (Aalborg, DK)
Abstract Slides Video
Presentation thumbnail
Non-clinical evaluation of YN001-a promising drug for atherosclerotic therapy by targeted delivery system
Doctor Q. Ma (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Combination of nicorandil and beta-adrenergic receptor blockers in patients with coronary heart disease: a real-world observational study
Professor N. Zhou (Wuhan, CN)
Abstract Slides Video
Presentation thumbnail
PSRC1 rs599839 G allele may promote protection from coronary artery disease in a Madeira Island population
Mr F. Sousa (Funchal, PT)
Abstract Slides Video
Presentation thumbnail
Effects on re-endothelialisation with Bydureon treatment add on to insulin versus insulin alone, both in combination with metformin in type 2 diabetic subjects: Rebuild study
Doctor I. Santos-Pardo (Badalona, ES)
Abstract Slides Video

Access the full session

Session thumbnail
Drug-related risk management in chronic coronary syndromes

The Event

Event poster

ESC Congress 2023

25 August 2023 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Exosomal preconditioning of human iPSC-derived cardiomyocytes beneficially alter cardiac electrophysiology during hypoxia.
thumbnail
Congress Session
Young Investigator Award Session in Basic and Translational Sciences
thumbnail
Congress Presentation
Cardiomyocyte-derived exosomes: linking heart failure to tumour progression

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources